

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **Alasdair M. Naylor, et al** :

APPLICATION NO.: **To be assigned** : Examiner: **To be assigned**

FILING DATE: **Filed herewith** : Group Art Unit: **To be assigned**

TITLE: **Treatment of Male Sexual Dysfunction** :

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

IN THE SPECIFICATION

Please insert the following sentences after the Title and prior to the first line.

--This application is a continuation-in-part of U.S. application serial no. 09/895,367 which was filed on June 29, 2001 which claims priority from U.S. provisional application 60/265,358 which was filed on January 31, 2001 and United Kingdom application 0030647.2 which was filed on December 15, 2000. This application is also a continuation-in-part of U.S. application serial no. 09/905,846 filed July 13, 2001. This application also claims priority from U.S. provisional application 60/291,722 filed May 17, 2001, U.K. provisional application 0108730.3 filed April 6, 2001, U.K. provisional application serial no. 0109910.0 filed April 23, 2001, U.K. provisional application 0111037.8 filed May 4, 2001 and U.K. application 0120679.6 filed August 24, 2001.--

IN THE CLAIMS

Please Cancel Claims 1 and 2.

Please amend claim 3 as follows:

Claim 3 (Amended) A method according to claim 13 wherein said inhibitor when in use is highly selective for NPY/NPY Y1 located in male genitalia.

Please amend claim 4 as follows:

Claim 4 (Amended) A method according to claim 14 wherein said inhibitor has no, or substantially no, activity towards endopeptidase NEP and/or angiotensin converting enzyme.

Please amend claim 5 as follows: